{"id":"exalamide","rwe":[],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"phase_2","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"allNames":"hyperan","offLabel":[],"synonyms":["exalamide","2-n-Hexyloxybenzamide","hyperan"],"timeline":[],"approvals":[],"brandName":"Hyperan","ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Imagine your body's cells have locks on them, and the key to unlocking the right response is a specific molecule. Exalamide is designed to fit that key and turn it to help your body respond in a healthy way. This can help to treat various conditions by restoring balance to your body's functions.","oneSentence":"Exalamide works by interacting with a specific molecular target to produce a therapeutic effect.","technicalDetail":"Exalamide's mechanism of action is not well understood, but it is believed to interact with a specific molecular target to produce a therapeutic effect. Further research is needed to elucidate its precise mechanism of action and to understand how it produces its effects in the body."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/1119","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=EXALAMIDE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:29:29.166376","biosimilars":[],"competitors":[],"genericName":"exalamide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"7JEC65JCG2","CHEBI":"CHEBI:31585","INN_ID":"4257","UMLSCUI":"C0046146","ChEMBL_ID":"CHEMBL1405973","KEGG_DRUG":"D01585","PUBCHEM_CID":"3316","SNOMEDCT_US":"703415004"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":2,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","companyName":"","companyId":"","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Exalamide, also known as Hyperan, is a small molecule modality with unknown target and drug class. Its commercial status is unclear, and it is not known if it is FDA approved or off-patent. There is limited information available on its approved indications, half-life, bioavailability, and generic manufacturers. Further research is needed to understand its clinical use and safety profile. As a result, it is not possible to provide a comprehensive summary of its key safety considerations.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}